Allogeneic CART progress: platforms, current progress and limitations
Allogenic chimeric antigen receptor T (CAR-T) cells have advantages compared to autologous T cell therapies such as availability cells for production, a suitable HLA-matched donor (if graft-vs-host-disease and rejection effects are to be avoided and also lower risks associated with transduction meth...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1557157/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850160973828063232 |
|---|---|
| author | Ameneh Shokati Maryam Sanjari-Pour Mahshid Akhavan Rahnama Saghar Hoseinzadeh Mohammad Vaezi Mohammad Ahmadvand |
| author_facet | Ameneh Shokati Maryam Sanjari-Pour Mahshid Akhavan Rahnama Saghar Hoseinzadeh Mohammad Vaezi Mohammad Ahmadvand |
| author_sort | Ameneh Shokati |
| collection | DOAJ |
| description | Allogenic chimeric antigen receptor T (CAR-T) cells have advantages compared to autologous T cell therapies such as availability cells for production, a suitable HLA-matched donor (if graft-vs-host-disease and rejection effects are to be avoided and also lower risks associated with transduction methods in process of autologous CAR-T cells). In recent years, the additional editing and non-editing technologies are helping to make allogenic CAR-T therapies a hopeful future treatment. Universal off-the-shelf CAR-T cells can be solved key issues include preventing graft-versus-host disease (GVHD) and time consumption and other challenges faced to allogenic CAR-T cells. Here, we have highlighted the improvement in CAR-T development, particularly in engineering allogenic CAR-T, clinical practices related to these, pre-clinical and clinical studies and their successes which investigated in recent 10 years related to treatment of hematological malignancies and cancers by allogenic CAR-T cells. |
| format | Article |
| id | doaj-art-8d9160dda20c4be4b8b0f4ce7d5e9a81 |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-8d9160dda20c4be4b8b0f4ce7d5e9a812025-08-20T02:23:00ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-06-011610.3389/fimmu.2025.15571571557157Allogeneic CART progress: platforms, current progress and limitationsAmeneh Shokati0Maryam Sanjari-Pour1Mahshid Akhavan Rahnama2Saghar Hoseinzadeh3Mohammad Vaezi4Mohammad Ahmadvand5Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Clinical Biochemistry, Faculty of Medical Science, Tarbiat Modarres University, Tehran, IranCell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, IranDepartment of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, IranCell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, IranCell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, IranAllogenic chimeric antigen receptor T (CAR-T) cells have advantages compared to autologous T cell therapies such as availability cells for production, a suitable HLA-matched donor (if graft-vs-host-disease and rejection effects are to be avoided and also lower risks associated with transduction methods in process of autologous CAR-T cells). In recent years, the additional editing and non-editing technologies are helping to make allogenic CAR-T therapies a hopeful future treatment. Universal off-the-shelf CAR-T cells can be solved key issues include preventing graft-versus-host disease (GVHD) and time consumption and other challenges faced to allogenic CAR-T cells. Here, we have highlighted the improvement in CAR-T development, particularly in engineering allogenic CAR-T, clinical practices related to these, pre-clinical and clinical studies and their successes which investigated in recent 10 years related to treatment of hematological malignancies and cancers by allogenic CAR-T cells.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1557157/fullallogeneic CAR T cellsediting technologynon-editing technologyoff-the-shelf CART cellgraft-versus-host disease |
| spellingShingle | Ameneh Shokati Maryam Sanjari-Pour Mahshid Akhavan Rahnama Saghar Hoseinzadeh Mohammad Vaezi Mohammad Ahmadvand Allogeneic CART progress: platforms, current progress and limitations Frontiers in Immunology allogeneic CAR T cells editing technology non-editing technology off-the-shelf CART cell graft-versus-host disease |
| title | Allogeneic CART progress: platforms, current progress and limitations |
| title_full | Allogeneic CART progress: platforms, current progress and limitations |
| title_fullStr | Allogeneic CART progress: platforms, current progress and limitations |
| title_full_unstemmed | Allogeneic CART progress: platforms, current progress and limitations |
| title_short | Allogeneic CART progress: platforms, current progress and limitations |
| title_sort | allogeneic cart progress platforms current progress and limitations |
| topic | allogeneic CAR T cells editing technology non-editing technology off-the-shelf CART cell graft-versus-host disease |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1557157/full |
| work_keys_str_mv | AT amenehshokati allogeneiccartprogressplatformscurrentprogressandlimitations AT maryamsanjaripour allogeneiccartprogressplatformscurrentprogressandlimitations AT mahshidakhavanrahnama allogeneiccartprogressplatformscurrentprogressandlimitations AT sagharhoseinzadeh allogeneiccartprogressplatformscurrentprogressandlimitations AT mohammadvaezi allogeneiccartprogressplatformscurrentprogressandlimitations AT mohammadahmadvand allogeneiccartprogressplatformscurrentprogressandlimitations |